Health Canada NPN Applications & Product Licensing

Health Canada reports that prioritized applications exceed review capacity. For applications received on or after 15 December 2025, review order follows receipt date. Earlier files follow workload-management prioritization-form dates, with receipt date breaking ties.

Review quality procedures and supplier records against GUI-0158 version 4. GMP responsibilities and the activities requiring a site licence should be assessed separately; not every business in the distribution chain needs the same licence.

Current labelling guidance identifies this date following the exemption order. Further regulatory amendments are being developed. Plan bilingual artwork and Product Facts Table requirements using the guidance in force, and recheck before printing.

The consultation page still describes a draft revised guide and says a final version is intended later in 2026. The end of consultation does not make the draft effective. Use current requirements while assessing potential changes.

The notice covers sports electrolyte products presented as foods. New products must meet the food framework. Oral rehydration solutions for diarrhea or vomiting are excluded; products with both ORS and sports claims need a positioning decision.

Health Canada says implementation did not proceed on the proposed 1 December 2025 date and will be revisited after program adjustments. Do not use the proposed fee tables as current charges. Consulting, testing and other project costs remain separate.

Pouches delivering 4 mg or less remain non-prescription products regulated as NHPs; those delivering more than 4 mg are prescription drugs. Ingredient amount alone does not authorize a product, claim or sales channel.

NHP describes the product category: a natural health product. An NPN is the product licence number assigned by Health Canada to an authorized NHP. Homeopathic products use a DIN-HM. An application in progress is not an issued licence.

We can assess the likely route from the full formula, ingredient forms, dose, claims and intended users. A short ingredient list alone is rarely enough. Our assessment supports planning; Health Canada makes the regulatory decision.

We scope the work after reviewing the product and available documentation. Cost depends on application complexity, evidence work, formula readiness, label support and the number of products. Ask for a written scope that separates consulting work from laboratory testing, translation, supplier work and any applicable external charges.

There are two timelines: preparing a complete submission and Health Canada reviewing it. Missing supplier records, evidence gaps and formula changes affect preparation. Review time depends on the application and applicable service standards. We agree preparation milestones after the initial review rather than promise an approval date.

Yes. We can review the scientific rationale, proposed use and supporting records, identify gaps and plan the application work. An ingredient being novel does not mean that a claim will be accepted. Some projects need additional evidence, a different claim or formulation changes before submission is practical.

We review it as a starting document and identify what needs to change for the Canadian product. Ingredient presentation, claims, directions, risk wording and bilingual information should be assessed together. Overseas sales history does not replace Canadian product authorization.

We can help define testing needs, coordinate third-party laboratory discussions and review available specifications and reports within the project scope. Laboratory fees and testing timelines are separate from application preparation unless expressly included in the proposal.

A product licence and a site licence serve different purposes. Canadian businesses manufacturing, packaging, labelling or importing NHPs for sale require the appropriate site licence. Your business activities and supply chain determine what applies; the NPN alone does not cover these activities.

Yes. We can assess your product for the Canadian market and help organize the application and local supply-chain requirements. We clarify applicant responsibilities, Canadian representation where applicable, and the licensed importing arrangement as part of the project.

We can review the file and discuss a defined handover. Start with the complete submission, correspondence, reference numbers and any deadline. Access and authorization must be arranged before we act on the file.

Submitting an application does not authorize sale. An NHP needs the applicable product licence before legal sale in Canada. The commercial launch also needs an appropriate manufacturing, import and labelling arrangement.

That is a useful time to start. We can connect the intended claims and regulatory route with formulation development, then identify the technical information a future manufacturing partner will need.